Thermo Fisher Scientific Proteomics Facility for Disease Target Discovery Opens at Gladstone Institutes
The Thermo Fisher Scientific Proteomics Facility for Disease Target Discovery has opened at the Gladstone Institutes, as part of a collaboration between Thermo Fisher, Gladstone, the University of California, San Francisco (UCSF), and QB3, to accelerate targeted proteomics research using the most advanced mass spectrometry technologies.
The Thermo Fisher Scientific Proteomics Facility is directed by Nevan J. Krogan, senior investigator at the Gladstone Institutes, professor of cellular and molecular pharmacology at UCSF, and director of the UCSF division of the life science research institute and startup accelerator QB3. The facility will provide scientists from Gladstone, UCSF, and QB3 with state-of-the-art mass spectrometry technologies to characterize protein dynamics in complex biological systems. The technologies will enable scientists to acquire unprecedented knowledge about the interactions between genes and the proteins they produce, and help facilitate solutions to unanswered biomedical problems.
Among the various cutting-edge approaches available in the Thermo Fisher Scientific Proteomics Facility are
• Creation of high-resolution protein-protein interaction maps and advanced protein characterization
• Genome-directed proteomic screening and selection
• Ultra-sensitive, quantitative analysis of protein abundance and post-translational modifications.
“We know that human cells contain approximately 25,000 genes that instruct the synthesis of many thousands of proteins, but we understand the function of only a small subset of these,” said R. Sanders Williams, president and Robert W. and Linda L. Mahley Distinguished Professor, Gladstone Institutes. “We are deeply grateful to Thermo Fisher for sponsoring this indispensable facility, which will not only illuminate how genes and proteins function but also shed light on the underlying biology of disease for each person.”
The facility will showcase the latest mass spectrometers for detailed biological discovery and quantitation, including the new Orbitrap Fusion Tribrid and TSQ Quantiva Triple Quadrupole LC/MS systems. In addition to enabling innovative research, the Thermo Fisher facility will be a focal point for promoting biological applications of mass spectrometry by hosting an invited lecture series, discussion groups, workshops, and trainings.
“Gladstone, UCSF, QB3, and Dr Krogan’s lab, including key members such as Jeffrey Johnson, have been doing exceptional work in the area of genetic and protein mapping in order to gain insight into disease pathways and mutations,” said Ken Miller, vice president, research product marketing, Thermo Fisher. “Through our collaboration, the new facility will enable researchers to apply state-of-the-art proteomics technologies to this critical area of research. We look forward to building on this collaboration and seeing the promising discoveries to come.”
“The new Thermo Fisher-sponsored facility will be of great benefit to researchers throughout the UCSF community and beyond,” said Sam Hawgood, MBBS, chancellor of UCSF. “By using these Thermo Fisher technologies, scientists will succeed in building comprehensive maps of how genes and proteins interact — knowledge that may lead to new drug targets for a host of devastating diseases.”
“Thermo Fisher is the perfect partner for this collaboration, both in terms of their technology and their willingness to support and grow the proteomics community,” stated Dr Krogan. “Our research is critically dependent on our ability to perform detailed protein analysis with extreme sensitivity and accuracy. We require the most advanced mass spectrometers to continue our studies.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance